The Anti-allergic Cromones: Past, Present, and Future

@article{Sinniah2017TheAC,
  title={The Anti-allergic Cromones: Past, Present, and Future},
  author={Ajantha Sinniah and Samia Yazid and Roderick John Flower},
  journal={Frontiers in Pharmacology},
  year={2017},
  volume={8}
}
The anti-allergic cromones were originally synthesized in the 1960s by Fisons Plc, and the first drug to emerge from this program, disodium cromoglycate was subsequently marketed for the treatment of asthma and other allergic conditions. Whilst early studies demonstrated that the ability of the cromones to prevent allergic reactions was due to their ‘mast cell stabilizing’ properties, the exact pharmacological mechanism by which this occurred, remained a mystery. Here, we briefly review the… Expand
Important antihistaminic plants and their potential role in health
TLDR
In this chapter, the relevant use of plants from folk medicine or scientific-based evidence for natural antiallergic drugs are highlighted, with special emphasis on the natural compounds with reported anti-allergic activity. Expand
Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19
TLDR
This commentary elaborates on the pharmacological rationale of repositioning the mast cell stabilizer chromones as an adjunctive treatment for SARS‐CoV‐2 infection, and proposes their practical clinical testing as an early, safe, and cost-effective anti-inflammatory intervention in COVID-19 to limit the eventual secondary progression toward life-threatening respiratory complications. Expand
Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents
TLDR
The complex pathophysiology of AR is described and the mechanism(s) of action) of topical treatments including antihistamines, steroids, anticholinergics, decongestants and chromones in relation to AR Pathophysiology are identified. Expand
Cromolyn inhibits the secretion of inflammatory cytokines by human microglia (HMC3)
TLDR
The results bolster the understanding of how the cromolyn platform modulates toxic microglia behavior as a dynamic future treatment option for neurodegenerative disorders. Expand
Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer
TLDR
Pharmacokinetic data of a novel high concentration formulation of CS (PA101) delivered via a high-efficiency nebulizer (eFlow®) in healthy volunteers (HVs), allergic asthmatics and patients with indolent systemic mastocytosis (ISM) and PA101 via eFlow® yielded comparable PK profiles in HVs and patients are presented. Expand
Novel Strategies to Target Mast Cells in Disease
TLDR
The currently available and emerging regimens to interfere with harmful mast cell activities in asthma and other pathological settings are reviewed and the advantages and limitations of such strategies are discussed. Expand
Tackling the cytokine storm in COVID-19, challenges and hopes
TLDR
This review critically compared the clinical impact of several potential therapeutic agents that could block or interfere with the cytokine storm, such as IL-1 inhibitors, IL-6 inhibitors, mast cell targeting agents, and corticosteroids. Expand
Design of Potential Pharmaceutical-Based Metal Complexes Derived from Cromolyn a Mast Cell Stabilizer
TLDR
A series of pharmaceutical metal complexes (pMCs) were produced and characterized using the mast cell stabilizer, cromolyn, and bioactive metal ions, and a variety of binding modes and packing motifs were found within each respective metal complex. Expand
Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells
TLDR
Evidence that a cytokine response by mast cells may initiate inappropriate antiviral immune responses and cause the development of cytokine storm syndrome is presented and the potential of mast cell activators as adjuvants for COVID-19 vaccines is explored. Expand
Design, synthesis, and biological evaluation of 2‐substituted‐2,3,4,9‐tetrahydrospiro‐β‐carboline‐3‐carboxylic acid derivatives as first‐in‐class mast cell stabilizers
TLDR
This is a seminal study of spiro‐β‐carboline mast cell stabilization having a wider scope in mast cell research; yet, the mechanism of action remains elusive. Expand
...
1
2
...

References

SHOWING 1-10 OF 139 REFERENCES
Inhibition of immediate hypersensitivity reactions by disodium cromoglycate.
TLDR
It is suggested that disodium cromoglycate may act by releasing some factor capable of inhibiting the release of mediators from the mast cell as well as inhibit IgE-mediated cutaneous anaphylaxis in the rat in vivo and release of histamine from peritoneal mast cells in vitro. Expand
Development of Preclinical Models for Testing Antiasthma Drugs
TLDR
The use of a model of immune lung inflammation in macaque monkeys in conjunction with a models of bronchial hyper-reactivity in the dog has been successful in producing the new compound, nedocromil sodium, which is proving to be an effective addition to the drugs available for the treatment of inflammatory diseases of the airways. Expand
Disodium Cromoglycate (FPL 670) (‘Intal’*): a Specific Inhibitor of Reaginic Antibody–Antigen Mechanisms
  • J. Cox
  • Chemistry, Medicine
  • Nature
  • 1967
TLDR
A disodium cromoglycate derivatives exhibiting unusual biological activity has been found to inhibit specifically the liberation of the mediators of anaphylaxis initiated by the interaction of antigen with reagin type antibodies. Expand
Anti-Allergic Cromones Inhibit Histamine and Eicosanoid Release from Activated Human and Murine Mast Cells by Releasing Annexin A1
Background and Purpose Although the ‘cromones’ (di-sodium cromoglycate and sodium nedocromil) are used to treat allergy and asthma, their ‘mast cell stabilising’ mechanism of pharmacological actionExpand
Anti-allergic drugs and the Annexin-A1 system.
TLDR
Some recent work from the authors' laboratory is described that provides a tentative explanation for the anti-inflammatory effects produced by the cromoglycate-like anti-allergic drugs. Expand
Two distinct anti-allergic drugs, amlexanox and cromolyn, bind to the same kinds of calcium binding proteins, except calmodulin, in bovine lung extract.
TLDR
Two anti-allergic drugs, amlexanox and cromolyn, which inhibit IgE mediated degranulation of mast cells and basophils, are used as molecular probes in affinity chromatography to explore candidates for proteins required in exocytosis. Expand
Alkaline phosphatase inhibition by a series of pyrido[2,1-b]quinazolines: A possible relationship with cromolyn-like antiallergy activity.
TLDR
A comparison of ALP and rat passive cutaneous anaphylaxis (PCA) inhibition indicates that PCA inhibition may be associated with drug-ALP interaction, and suggests that alkaline phosphatase may be a component of membranal calcium channels. Expand
Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family.
TLDR
It is speculated that the three anti-allergic drugs might inhibit degranulation by binding with S 100A12 and S100A13, which are known to bind to immobilized amlexanox and tranilast. Expand
Studies on the mechanism of tachyphylaxis to disodium cromoglycate.
TLDR
The tachyphylaxis to disodium cromoglycate's (DSCG) inhibition of antigen-induced histamine release is readily demonstrable utilizing passively sensitized rat lung fragments and is evident whether or not calcium is present during drug preincubation. Expand
Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation.
TLDR
Current understanding of how anti-histamines and mast cell stabilizers work is discussed, particularly in the context of molecular mechanisms of ocular allergic inflammation. Expand
...
1
2
3
4
5
...